Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Horizons Ventures
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | Dec 20, 2023
Deals
Dec. 19 Quick Takes: Ionis, Otsuka in European deal for HAE therapy
Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL
BioCentury | Dec 4, 2023
Deals
Move into obesity will require deep spending by Roche
After $2.7B takeout of Carmot, bigger investment for Roche will come with development programs, commercial buildup to compete with Novo Nordisk and Lilly
BioCentury | Nov 8, 2022
Emerging Company Profile
Juvena: taking on aging with secreted proteins
Bay Area biotech is finding secreted proteins for age-related diseases systematically
BioCentury | Nov 4, 2022
Regulation
Nov. 3 Quick Takes: FDA delay could shorten Apellis’ lead in geographic atrophy
Plus NextCure abandons SIGLEC15 and updates from Emalex, Moderna, Aurinia, Affimed, Artiva and more
BioCentury | Aug 25, 2022
Deals
Aug. 24 Quick Takes: EC approves BioMarin’s hemophilia A gene therapy
Plus Ovid, Gensaic in gene therapy deal and updates from Digital Diagnostics, BioInnovation Institute, Moderna, Relief and more
BioCentury | Jul 26, 2022
Finance
Carmot deepens commitment to metabolic pipeline with $160M series D
Biotech believes dual modulator could be best in a class that includes Lilly’s Mounjaro
BioCentury | Jul 15, 2022
Politics, Policy & Law
July 14 Quick Takes: Illumina, BGI end U.S. legal battle
Plus FDA delays BeiGene’s BLA, Manifold raises $40M and updates from Theravance, Marinus, and more
BioCentury | Jul 13, 2022
Emerging Company Profile
Epic Bio: Epigenome editing via compact components
Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
BioCentury | Apr 28, 2022
Emerging Company Profile
Kelonia: redirecting in vivo gene therapy
Kelonia has a team of bluebird veterans and a $50 million series A round to tackle gene therapy’s delivery problem
Items per page:
1 - 10 of 24